MTEM - Molecular Templates Inc
Previous close
1.52
0 0%
Share volume: 2,292
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.52
0.00
0.00%
Fundamental analysis
25%
Profitability
25%
Dept financing
24%
Liquidity
31%
Performance
25%
Performance
5 Days
-0.65%
1 Month
-3.16%
3 Months
25.41%
6 Months
-60.16%
1 Year
-82.00%
2 Year
-85.92%
Key data
Stock price
$1.52
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.01 - $8.73
52 WEEK CHANGE
-$0.82
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Eric Poma
Region: US
Website: https://mtem.com/
Employees: 205
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://mtem.com/
Employees: 205
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.
Recent news